中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS
News
Careers
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Show More
2015
2014
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-03-10
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
2020-02-27
Ascletis’ IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
2020-02-18
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
2020-01-23
«
1
2
3
浙公网安备 33010802003344号 浙ICP备11050387号-1